A review of vaccines for HIV prevention

Journal of Gene Medicine

Volumn 5, Issue 1, 2003, Pages 3-10

  Mwau, Matilu ^a   McMichael, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

DNA vaccine; HIV; MVA; T cells

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE; CYTOKINE; DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HIVA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISCOM; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NYVAC; PEPTIDE DERIVATIVE; PLASMID DNA; PROTEIN SUBUNIT; TRANSACTIVATOR PROTEIN; UBI HIV IMN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIOR MODIFICATION; CLINICAL TRIAL; CULTURAL FACTOR; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG FORMULATION; ECONOMICS; ERYTHEMA; GENE GUN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NONHUMAN; PATIENT ATTITUDE; POXVIRUS; PRIORITY JOURNAL; PRURITUS; PUBLIC HEALTH SERVICE; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SIDE EFFECT; SINDBIS VIRUS; SKIN INDURATION; SOCIAL ASPECT; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; IMMUNOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS; HUMANS;

EID: 0038639684     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.343     Document Type: Review

References (116)

1. Rowland-Jones S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
2. Rowland-Jones SL, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102: 1758-1765.
3. Murthy KK, et al. Correlates of protective immunity against HIV-1 infection in immunized chimpanzees. Immunol Lett 1996; 51: 121-124.
4. Clerici M, Shearer GM. Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol Lett 1996; 51: 69-73.
5. Kaul R, et al. HIV-1-specific mucosal GD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164: 1602-1611.
6. Kaul R, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre- existing HIV-specific CD8+ responses. J Clin Invest 2001; 107: 341-349.
7. Kent SJ, Woodward A, Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J Infect Dis 1997; 176: 1188-1197.
8. Rowland-Jones SL, et al. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors. Immunol Lett 1999; 66: 9-14.
9. Walker CM. Non-cytolytic control of HIV replication by CD8+ T cells. Semin Immunol 1993; 5: 195-201.
10. Walker CM, et al. CD8+ T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses. Cell Immunol 1991; 137: 420-428.
11. Barouch DH, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001; 75: 5151-5158.
12. Barouch DH, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486-492.
13. Amara RR, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
14. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody - debris or virion? Nat Med 1997; 3: 366-367.
15. Parren PW, et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. Aids 1999; 13: S137-162.
16. Burton DR, Williamson RA, Parren PW. Antibody and virus: binding and neutralization. Virology 2000; 270: 1-3.
17. Burton DR, Montefiori DC. The antibody response in HIV-1 infection. Aids 1997; 11: S87-98.
18. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A 1997; 94:10 018-10 023.
19. Botarelli P, et al. N-Glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol 1991; 147: 3128-3132.
20. Mo H, et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol 1997; 71: 6869-6874.
21. Pincus SH, et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol 1997; 158 3511-3520.
22. Cox JH, et al. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. AIDS Res Hum Retroviruses 1999; 15: 847-854.
23. Montefiori DC, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996; 173: 60-67.
24. Pilgrim AK, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176: 924-932.
25. Stiehm ER, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis 2000; 181: 548-554.
26. Borrow P, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
27. Gallimore A, et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995; 1: 1167-1173.
28. Schmitz JE, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-860.
29. Hansburg D, et al. Major histocompatibility complex-controlled, antigen-presenting cell-expressed specificity of T cell antigen recognition. Identification of a site of interaction and its relationship to Ir genes. J Exp Med 1983; 158: 25-39.
30. Williams NS, Engelhard VH. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells: J Immunol 1997; 159: 2091-2099.
31. Kaslow RA, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2: 405-411.
32. Carrington M, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 1748-1752.
33. Hadida F, et al. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J Immunol 1999; 163: 1105-1109.
34. Meylan PR, et al. Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. Virology 1993; 193: 138-148.
35. Cocchi F, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
36. Goulder PJ, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3: 212-217.
37. Goulder PJ, Walker BD. The great escape - AIDS viruses and immune control. Nat Med 1999; 5: 1233-1235.
38. Kelleher AD, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193: 375-386.
39. McKeating JA, et al. Characterization of HIV-1 neutralization escape mutants. Aids 1989; 3: 777-784.
40. Kerkau T, et al. Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 1989; 5: 613-620.
41. Puppo F, et al. Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals. AIDS Res Hum Retroviruses 1997; 13: 1509-1516.
42. Appay V, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192: 63-75.
43. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
44. Chun TW, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13 193-13 197.
45. Putkonen P, et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med 1995; 1: 914-918.
46. Wyand MS, et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73: 8356-8363.
47. Johnson RP, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999; 73: 4952-4961.
48. Wyand MS, et al. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med 1997; 3: 32-36.
49. Baba TW, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994; 10 351-357.
50. Baba TW, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5: 194-203.
51. Moss RB, et al. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine 2000; 18: 1081-1087.
52. Limsuwan A, et al. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects. Vaccine 1998; 16: 142-149.
53. Tian H, et al. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies. Int Immunopharmacol 2001; 1: 763-768.
54. O'Hagan DT, et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 2000; 18: 1793-1801.
55. McFarland EJ, et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 2001; 184: 1331-1335.
56. Nitayaphan S, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 2000; 18: 1448-1455.
57. Heeney J, et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999; 66: 189-195.
58. Francis DP, et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14(Suppl 3): S325-331.
59. Francis DP. AIDSVAX is safe, but efficacy question remains. VaxGen founder discusses quest for AIDS vaccine. Aids Alert 2001; 16: 141-142, 147.
60. Berglund P, et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997; 13: 1487-1495.
61. Belyakov IM, et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998; 72 8264-8272.
62. Barouch DH, et al. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett 2001; 79: 57-61.
63. Barouch DH, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415: 335-339.
64. Barouch DH, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161: 1875-1882.
65. Montefiori DC, et al. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. J Clin Invest 1993; 92: 840-847.
66. Lee SA, et al. Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates. Vaccine 2001; 20: 563-576.
67. Abimiku AG, et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1995; 1: 321-329.
68. Tartaglia J, et al. Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 1992; 8: 1445-1447.
69. Brand D, et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki forest virus RNA, or recombinant Semliki forest virus particles. AIDS Res Hum Retroviruses 1998; 14: 1369-1377.
70. Mossman SP, et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996; 70: 1953-1960.
71. Natuk RJ, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993; 9: 395-404.
72. Natuk RJ, et al. Adenovirus vectored vaccines. Dev Biol Stand 1994; 82: 71-77.
73. Lubeck MD, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994; 10 1443-1449.
74. Villacres MC, Zuo J, Bergmann CC. Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses. Virology 2000; 270: 54-64.
75. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991; 351 479-482.
76. Ferrari G, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000; 16: 1433-1443.
77. Falk LA, et al. Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines. AIDS Res Hum Retroviruses 2000; 16: 91-98.
78. Stover CK, et al. New use of BGG for recombinant vaccines. Nature 1991; 351: 456-460.
79. Di Fabio S, et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 1998; 16: 485-492.
80. Wu S, et al. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res Hum Retroviruses 1997; 13: 1187-1194.
81. Fouts TR, et al. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 1995; 13: 1697-1705.
82. Fouts TR, Lewis GK, Hone DM. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. Vaccine 1995; 13: 561-569.
83. Guzman CA, et al. Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells. Eur J Immunol 1998; 28: 1807-1814.
84. Friedman RS, et al. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Virol 2000; 74: 9987-9993.
85. Mata M, et al. Evaluation of a recombinant Listeria monocytogene expressing an HIV protein that protects mice against viral challenge. Vaccine 2001; 19: 1435-1445.
86. Van Rompay KK, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection, J Infect Dis 1998; 177: 1247-1259.
87. Shata MT, et al. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001; 20: 623-629.
88. Mascola JR, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018.
89. Mascola JR, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210.
90. Okamoto Y, et al. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate. J Immunol 1998; 160: 69-76.
91. Safrit JT, et al. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. Aids 1993; 7: 15-21.
92. Nishimura Y, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76: 2123-2130.
93. Shibata R, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5 204-210.
94. Lebedev LR, et al. Design of virus-like particles, exposing HIV-1 epitopes. Mol Biol (Moscow) 2000; 34: 480-485.
95. Akahata W, et al. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles. Virology 2000; 275: 116-124.
96. Liu XS, et al. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998; 252: 39-45.
97. Klein MR, et al. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 1997; 13 393-399.
98. Haynes BF, et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993; 151: 1646-1653.
99. Pialoux G, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995; 11: 373-381.
100. Hanke T, et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 1998; 79: 83-90.
101. Hanke T, et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 1999; 17: 589-596.
102. Hanke T, McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 1999; 66: 177-181.
103. Estcourt MJ, et al. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 2002; 14: 31-37.
104. Fuller DH, et al. Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J Med Primatol 1996; 25: 236-241.
105. Prayaga SK, Ford MJ, Haynes JR. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization. Vaccine 1997; 15: 1349-1352.
106. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year - 2000 clinical trial in Kenya. Nat Med 2000; 6: 951-955.
107. Mwau M, McMichael AJ, Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 2002; 18: 611-618.
108. Amara RR, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76: 7625-7631.
109. Shiver JW, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331-335.
110. Kaul R, et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001; 79: 3-13.
111. Migasena S, et al. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses 2000; 16: 655-663.
112. Turner JL, et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001; 2: 68-77.
113. Sukeepaisarncharoen W, et al. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy. HIV Clin Trials 2001; 2: 391-398.
114. Cox WI, Tartaglia J, Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993; 195: 845-850.
115. Lambert JS, et al. A phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19: 3033-3042.
116. Kelleher AD, et al. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses 1997; 13: 29-32.